APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK1/NK3 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

NK1/NK3 Receptor Antagonists Industry Research Report 2026

23 December 2025130 pages

Choose your research edition.

Industry ResearchNK1/NK3 Receptor Antagonists Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NK1/NK3 Receptor Antagonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for NK1/NK3 Receptor Antagonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for NK1/NK3 Receptor Antagonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of NK1/NK3 Receptor Antagonists include Chia Tai Tianqing Pharmaceutical, Yichang Humanwell Pharmaceutical, Qilu Pharmaceutical, Merck, Luoxin Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Helsinn Healthcare, Hansoh Pharma and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global NK1/NK3 Receptor Antagonists market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

NK1/NK3 Receptor Antagonists Market by Company

Chia Tai Tianqing Pharmaceutical

Yichang Humanwell Pharmaceutical

Qilu Pharmaceutical

Merck

Luoxin Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Helsinn Healthcare

Hansoh Pharma

Fresenius Kabi

Beijing Sihuan Pharmaceutical

Bayer

Astellas

Torrent Pharmaceuticals

TerSera Therapeutics

Heron Therapeutics

Glenmark

NK1/NK3 Receptor Antagonists Segment by Type

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

NK1/NK3 Receptor Antagonists Segment by Application

Hospital

Specialty Clinic

NK1/NK3 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1/NK3 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1/NK3 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1/NK3 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of NK1/NK3 Receptor Antagonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of NK1/NK3 Receptor Antagonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of NK1/NK3 Receptor Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global NK1/NK3 Receptor Antagonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global NK1/NK3 Receptor Antagonists Sales (k units) of Manufacturers (2021-2026) Table 7. Global NK1/NK3 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global NK1/NK3 Receptor Antagonists Revenue of Manufacturers (2021-2026) Table 9. Global NK1/NK3 Receptor Antagonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market NK1/NK3 Receptor Antagonists Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global NK1/NK3 Receptor Antagonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of NK1/NK3 Receptor Antagonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of NK1/NK3 Receptor Antagonists, Product Type & Application Table 14. Global NK1/NK3 Receptor Antagonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global NK1/NK3 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chia Tai Tianqing Pharmaceutical Company Information Table 19. Chia Tai Tianqing Pharmaceutical Business Overview Table 20. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 22. Chia Tai Tianqing Pharmaceutical Recent Developments Table 23. Yichang Humanwell Pharmaceutical Company Information Table 24. Yichang Humanwell Pharmaceutical Business Overview Table 25. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 27. Yichang Humanwell Pharmaceutical Recent Developments Table 28. Qilu Pharmaceutical Company Information Table 29. Qilu Pharmaceutical Business Overview Table 30. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 32. Qilu Pharmaceutical Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Merck NK1/NK3 Receptor Antagonists Product Portfolio Table 37. Merck Recent Developments Table 38. Luoxin Pharmaceutical Company Information Table 39. Luoxin Pharmaceutical Business Overview Table 40. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 42. Luoxin Pharmaceutical Recent Developments Table 43. Jiangsu Hengrui Pharmaceuticals Company Information Table 44. Jiangsu Hengrui Pharmaceuticals Business Overview Table 45. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 47. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 48. Helsinn Healthcare Company Information Table 49. Helsinn Healthcare Business Overview Table 50. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio Table 52. Helsinn Healthcare Recent Developments Table 53. Hansoh Pharma Company Information Table 54. Hansoh Pharma Business Overview Table 55. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio Table 57. Hansoh Pharma Recent Developments Table 58. Fresenius Kabi Company Information Table 59. Fresenius Kabi Business Overview Table 60. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio Table 62. Fresenius Kabi Recent Developments Table 63. Beijing Sihuan Pharmaceutical Company Information Table 64. Beijing Sihuan Pharmaceutical Business Overview Table 65. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 67. Beijing Sihuan Pharmaceutical Recent Developments Table 68. Bayer Company Information Table 69. Bayer Business Overview Table 70. Bayer NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Bayer NK1/NK3 Receptor Antagonists Product Portfolio Table 72. Bayer Recent Developments Table 73. Astellas Company Information Table 74. Astellas Business Overview Table 75. Astellas NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Astellas NK1/NK3 Receptor Antagonists Product Portfolio Table 77. Astellas Recent Developments Table 78. Torrent Pharmaceuticals Company Information Table 79. Torrent Pharmaceuticals Business Overview Table 80. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 82. Torrent Pharmaceuticals Recent Developments Table 83. TerSera Therapeutics Company Information Table 84. TerSera Therapeutics Business Overview Table 85. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 87. TerSera Therapeutics Recent Developments Table 88. Heron Therapeutics Company Information Table 89. Heron Therapeutics Business Overview Table 90. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 92. Heron Therapeutics Recent Developments Table 93. Glenmark Company Information Table 94. Glenmark Business Overview Table 95. Glenmark NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Glenmark NK1/NK3 Receptor Antagonists Product Portfolio Table 97. Glenmark Recent Developments Table 98. Global NK1/NK3 Receptor Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (k units) Table 100. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 101. Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032) & (k units) Table 102. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 103. Global NK1/NK3 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 104. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 105. Global NK1/NK3 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 106. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 107. North America NK1/NK3 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 109. North America NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 110. North America NK1/NK3 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 111. North America NK1/NK3 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe NK1/NK3 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 114. Europe NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 115. Europe NK1/NK3 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe NK1/NK3 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific NK1/NK3 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific NK1/NK3 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific NK1/NK3 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 122. South America NK1/NK3 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 124. South America NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 125. South America NK1/NK3 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 126. South America NK1/NK3 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa NK1/NK3 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa NK1/NK3 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa NK1/NK3 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 132. Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 133. Global NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 134. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 135. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 136. Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 137. Global NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 138. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 139. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 140. Global NK1/NK3 Receptor Antagonists Price by Type (2021-2026) & (USD/unit) Table 141. Global NK1/NK3 Receptor Antagonists Price by Type (2027-2032) & (USD/unit) Table 142. Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 143. Global NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 144. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 145. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 146. Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 147. Global NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 148. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 149. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 150. Global NK1/NK3 Receptor Antagonists Price by Application (2021-2026) & (USD/unit) Table 151. Global NK1/NK3 Receptor Antagonists Price by Application (2027-2032) & (USD/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. NK1/NK3 Receptor Antagonists Distributors List Table 155. NK1/NK3 Receptor Antagonists Customers List Table 156. NK1/NK3 Receptor Antagonists Industry Trends Table 157. NK1/NK3 Receptor Antagonists Industry Drivers Table 158. NK1/NK3 Receptor Antagonists Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. NK1/NK3 Receptor Antagonists Product Image Figure 5. Global NK1/NK3 Receptor Antagonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global NK1/NK3 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 7. Global NK1/NK3 Receptor Antagonists Sales (2021-2032) & (k units) Figure 8. Global NK1/NK3 Receptor Antagonists Average Price (USD/unit) & (2021-2032) Figure 9. NK1 Receptor Antagonist Product Image Figure 10. NK3 Receptor Antagonist Product Image Figure 11. Dual Antagonist Product Image Figure 12. Hospital Product Image Figure 13. Specialty Clinic Product Image Figure 14. Global NK1/NK3 Receptor Antagonists Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of NK1/NK3 Receptor Antagonists, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 NK1/NK3 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global NK1/NK3 Receptor Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global NK1/NK3 Receptor Antagonists Sales by Region in 2025 Figure 20. Global NK1/NK3 Receptor Antagonists Revenue by Region in 2025 Figure 21. North America NK1/NK3 Receptor Antagonists Market Size by Country in 2025 Figure 22. North America NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 23. North America NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 24. United States NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe NK1/NK3 Receptor Antagonists Market Size by Country in 2025 Figure 28. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 29. Europe NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 30. Germany NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific NK1/NK3 Receptor Antagonists Market Size by Country in 2025 Figure 41. Asia Pacific NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 43. China NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America NK1/NK3 Receptor Antagonists Market Size by Country in 2025 Figure 52. South America NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 53. South America NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 54. Brazil NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country in 2025 Figure 58. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 60. Egypt NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries NK1/NK3 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 66. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 67. Global NK1/NK3 Receptor Antagonists Price (USD/unit) by Type (2021-2032) Figure 68. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 69. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 70. Global NK1/NK3 Receptor Antagonists Price (USD/unit) by Application (2021-2032) Figure 71. NK1/NK3 Receptor Antagonists Value Chain Figure 72. NK1/NK3 Receptor Antagonists Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • NK1 Receptor Antagonist
  • NK3 Receptor Antagonist
  • Dual Antagonist
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Luoxin Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Helsinn Healthcare
  • Hansoh Pharma
  • Fresenius Kabi
  • Beijing Sihuan Pharmaceutical
  • Bayer
  • Astellas
  • Torrent Pharmaceuticals
  • TerSera Therapeutics
  • Heron Therapeutics
  • Glenmark

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global NK1/NK3 Receptor Antagonists Market Size (2021-2032)
  4. 2.2.2 Global NK1/NK3 Receptor Antagonists Sales (2021-2032)
  5. 2.2.3 Global NK1/NK3 Receptor Antagonists Market Average Price (2021-2032)
  6. 2.3 NK1/NK3 Receptor Antagonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 NK1 Receptor Antagonist
  9. 2.3.3 NK3 Receptor Antagonist
  10. 2.3.4 Dual Antagonist
  11. 2.4 NK1/NK3 Receptor Antagonists by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Specialty Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global NK1/NK3 Receptor Antagonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global NK1/NK3 Receptor Antagonists Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global NK1/NK3 Receptor Antagonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global NK1/NK3 Receptor Antagonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global NK1/NK3 Receptor Antagonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of NK1/NK3 Receptor Antagonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of NK1/NK3 Receptor Antagonists, Product Type & Application
  8. 3.8 Global Manufacturers of NK1/NK3 Receptor Antagonists, Established Date
  9. 3.9 Global NK1/NK3 Receptor Antagonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chia Tai Tianqing Pharmaceutical
  2. 4.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 4.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 4.1.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  6. 4.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 4.2 Yichang Humanwell Pharmaceutical
  8. 4.2.1 Yichang Humanwell Pharmaceutical Company Information
  9. 4.2.2 Yichang Humanwell Pharmaceutical Business Overview
  10. 4.2.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  12. 4.2.5 Yichang Humanwell Pharmaceutical Recent Developments
  13. 4.3 Qilu Pharmaceutical
  14. 4.3.1 Qilu Pharmaceutical Company Information
  15. 4.3.2 Qilu Pharmaceutical Business Overview
  16. 4.3.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  18. 4.3.5 Qilu Pharmaceutical Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck NK1/NK3 Receptor Antagonists Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Luoxin Pharmaceutical
  26. 4.5.1 Luoxin Pharmaceutical Company Information
  27. 4.5.2 Luoxin Pharmaceutical Business Overview
  28. 4.5.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  30. 4.5.5 Luoxin Pharmaceutical Recent Developments
  31. 4.6 Jiangsu Hengrui Pharmaceuticals
  32. 4.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 4.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 4.6.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  36. 4.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 4.7 Helsinn Healthcare
  38. 4.7.1 Helsinn Healthcare Company Information
  39. 4.7.2 Helsinn Healthcare Business Overview
  40. 4.7.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio
  42. 4.7.5 Helsinn Healthcare Recent Developments
  43. 4.8 Hansoh Pharma
  44. 4.8.1 Hansoh Pharma Company Information
  45. 4.8.2 Hansoh Pharma Business Overview
  46. 4.8.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio
  48. 4.8.5 Hansoh Pharma Recent Developments
  49. 4.9 Fresenius Kabi
  50. 4.9.1 Fresenius Kabi Company Information
  51. 4.9.2 Fresenius Kabi Business Overview
  52. 4.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio
  54. 4.9.5 Fresenius Kabi Recent Developments
  55. 4.10 Beijing Sihuan Pharmaceutical
  56. 4.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 4.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 4.10.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  60. 4.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 4.11 Bayer
  62. 4.11.1 Bayer Company Information
  63. 4.11.2 Bayer Business Overview
  64. 4.11.3 Bayer NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Bayer NK1/NK3 Receptor Antagonists Product Portfolio
  66. 4.11.5 Bayer Recent Developments
  67. 4.12 Astellas
  68. 4.12.1 Astellas Company Information
  69. 4.12.2 Astellas Business Overview
  70. 4.12.3 Astellas NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Astellas NK1/NK3 Receptor Antagonists Product Portfolio
  72. 4.12.5 Astellas Recent Developments
  73. 4.13 Torrent Pharmaceuticals
  74. 4.13.1 Torrent Pharmaceuticals Company Information
  75. 4.13.2 Torrent Pharmaceuticals Business Overview
  76. 4.13.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  78. 4.13.5 Torrent Pharmaceuticals Recent Developments
  79. 4.14 TerSera Therapeutics
  80. 4.14.1 TerSera Therapeutics Company Information
  81. 4.14.2 TerSera Therapeutics Business Overview
  82. 4.14.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  84. 4.14.5 TerSera Therapeutics Recent Developments
  85. 4.15 Heron Therapeutics
  86. 4.15.1 Heron Therapeutics Company Information
  87. 4.15.2 Heron Therapeutics Business Overview
  88. 4.15.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  90. 4.15.5 Heron Therapeutics Recent Developments
  91. 4.16 Glenmark
  92. 4.16.1 Glenmark Company Information
  93. 4.16.2 Glenmark Business Overview
  94. 4.16.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Glenmark NK1/NK3 Receptor Antagonists Product Portfolio
  96. 4.16.5 Glenmark Recent Developments
5 Global NK1/NK3 Receptor Antagonists Market Scenario by Region
  1. 5.1 Global NK1/NK3 Receptor Antagonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021-2032
  3. 5.2.1 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021-2026
  4. 5.2.2 Global NK1/NK3 Receptor Antagonists Sales by Region: 2027-2032
  5. 5.3 Global NK1/NK3 Receptor Antagonists Revenue by Region: 2021-2032
  6. 5.3.1 Global NK1/NK3 Receptor Antagonists Revenue by Region: 2021-2026
  7. 5.3.2 Global NK1/NK3 Receptor Antagonists Revenue by Region: 2027-2032
  8. 5.4 North America NK1/NK3 Receptor Antagonists Market Facts & Figures by Country
  9. 5.4.1 North America NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  11. 5.4.3 North America NK1/NK3 Receptor Antagonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe NK1/NK3 Receptor Antagonists Market Facts & Figures by Country
  16. 5.5.1 Europe NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  18. 5.5.3 Europe NK1/NK3 Receptor Antagonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific NK1/NK3 Receptor Antagonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific NK1/NK3 Receptor Antagonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America NK1/NK3 Receptor Antagonists Market Facts & Figures by Country
  41. 5.7.1 South America NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  43. 5.7.3 South America NK1/NK3 Receptor Antagonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa NK1/NK3 Receptor Antagonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa NK1/NK3 Receptor Antagonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  2. 6.1.1 Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  5. 6.2.1 Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global NK1/NK3 Receptor Antagonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  2. 7.1.1 Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  5. 7.2.1 Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global NK1/NK3 Receptor Antagonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 NK1/NK3 Receptor Antagonists Value Chain Analysis
  2. 8.1.1 NK1/NK3 Receptor Antagonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 NK1/NK3 Receptor Antagonists Production Mode & Process
  5. 8.2 NK1/NK3 Receptor Antagonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 NK1/NK3 Receptor Antagonists Distributors
  8. 8.2.3 NK1/NK3 Receptor Antagonists Customers
9 Global NK1/NK3 Receptor Antagonists Analyzing Market Dynamics
  1. 9.1 NK1/NK3 Receptor Antagonists Industry Trends
  2. 9.2 NK1/NK3 Receptor Antagonists Industry Drivers
  3. 9.3 NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges
  4. 9.4 NK1/NK3 Receptor Antagonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst